Caption Management’s Zevra Therapeutics ZVRA Stock Holding History

Caption Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.7M	Hold	2,002,800	–	–	0.13%	156
2026 Q1	$18.7M	Buy	2,002,800 +901,600	+82%	+$8.13M	0.11%	200
2025 Q4	$9.87M	Buy	1,101,200 +101,100	+10%	+$956K	0.07%	339
2025 Q3	$9.51M	Buy	1,000,100 +900,100	+900%	+$9.03M	0.07%	295
2025 Q2	$881K	Hold	100,000	–	–	0.01%	969
2025 Q1	$749K	Buy	+100,000	New	+$795K	0.01%	998
2022 Q4	–	Sell	-50,000	Closed	-$313K	–	1793
2022 Q3	$313K	Buy	+50,000	New	+$283K	﹤0.01%	1174
2022 Q2	–	Sell	-42,500	Closed	-$214K	–	1909
2022 Q1	$214K	Buy	+42,500	New	+$270K	﹤0.01%	1265

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caption Management's ZVRA Position: Q2 2026 in Review

Caption Management reduced its Zevra Therapeutics (ZVRA) stake by 53% in Q2 2026, selling an estimated $1.5M and leaving 120,000 shares worth $1.72M. The position accounts for 0.01% of the portfolio, ranked #953.

Caption Management first reported a position in ZVRA in Q4 2021 and has held it in 9 quarters since. The position peaked at $4.85M in Q3 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Caption Management held 120,000 shares of Zevra Therapeutics worth $1.72M as of Q2 2026.
Caption Management sold 135,236 Zevra Therapeutics shares in Q2 2026, an estimated $1.5M.
Zevra Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #953 holding.
Caption Management first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 9 quarters since.
Caption Management's Zevra Therapeutics position peaked at $4.85M in Q3 2025.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.